JP2006519862A5 - - Google Patents

Download PDF

Info

Publication number
JP2006519862A5
JP2006519862A5 JP2006509002A JP2006509002A JP2006519862A5 JP 2006519862 A5 JP2006519862 A5 JP 2006519862A5 JP 2006509002 A JP2006509002 A JP 2006509002A JP 2006509002 A JP2006509002 A JP 2006509002A JP 2006519862 A5 JP2006519862 A5 JP 2006519862A5
Authority
JP
Japan
Prior art keywords
aromatase inhibitor
cancer
letrozole
tumor
cci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/006354 external-priority patent/WO2004078133A2/en
Publication of JP2006519862A publication Critical patent/JP2006519862A/ja
Publication of JP2006519862A5 publication Critical patent/JP2006519862A5/ja
Pending legal-status Critical Current

Links

JP2006509002A 2003-03-05 2004-03-01 抗腫瘍剤の組み合わせ Pending JP2006519862A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45228903P 2003-03-05 2003-03-05
PCT/US2004/006354 WO2004078133A2 (en) 2003-03-05 2004-03-01 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor

Publications (2)

Publication Number Publication Date
JP2006519862A JP2006519862A (ja) 2006-08-31
JP2006519862A5 true JP2006519862A5 (cg-RX-API-DMAC7.html) 2007-04-12

Family

ID=32962706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509002A Pending JP2006519862A (ja) 2003-03-05 2004-03-01 抗腫瘍剤の組み合わせ

Country Status (20)

Country Link
US (1) US20040176339A1 (cg-RX-API-DMAC7.html)
EP (1) EP1603561A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006519862A (cg-RX-API-DMAC7.html)
KR (1) KR20050109965A (cg-RX-API-DMAC7.html)
CN (1) CN1756549A (cg-RX-API-DMAC7.html)
AR (1) AR043403A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004218439A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0408024A (cg-RX-API-DMAC7.html)
CA (1) CA2516353A1 (cg-RX-API-DMAC7.html)
CR (1) CR7942A (cg-RX-API-DMAC7.html)
EC (1) ECSP056001A (cg-RX-API-DMAC7.html)
MX (1) MXPA05009246A (cg-RX-API-DMAC7.html)
NI (1) NI200500148A (cg-RX-API-DMAC7.html)
NO (1) NO20054133L (cg-RX-API-DMAC7.html)
NZ (1) NZ542738A (cg-RX-API-DMAC7.html)
RU (1) RU2355399C2 (cg-RX-API-DMAC7.html)
TW (1) TW200529829A (cg-RX-API-DMAC7.html)
UA (1) UA83484C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004078133A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200508029B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
RU2345772C2 (ru) * 2003-07-25 2009-02-10 Уайт Лиофилизированные композиции cci-779
ES2298861T3 (es) * 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
KR20070070184A (ko) * 2004-10-28 2007-07-03 와이어쓰 자궁근종의 치료에 있어서 mTOR 억제제의 용도
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
JP2009516671A (ja) * 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト mTOR阻害剤を使用する神経内分泌腫瘍処置
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2010008744A2 (en) 2008-06-17 2010-01-21 Wyeth Antineoplastic combinations containing hki-272 and vinorelbine
RU2498804C2 (ru) 2008-08-04 2013-11-20 ВАЙЕТ ЭлЭлСи Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
CA2743242A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CN102612564B (zh) 2009-04-10 2015-08-26 齐海燕 新的抗衰老试剂及其鉴别方法
ES2694582T3 (es) 2011-01-31 2018-12-21 Lucolas-M.D. Ltd. Combinaciones de inhibidores de aromatasa y antioxidantes
US9682066B2 (en) * 2012-12-04 2017-06-20 University Of Cincinnati Methods of treating primary brain tumors by administering letrozole
WO2015014284A1 (zh) * 2013-07-31 2015-02-05 北京盛诺基医药科技有限公司 一种乳腺癌的治疗方法
MX381173B (es) 2013-10-08 2025-03-12 Ai Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
MX394266B (es) 2014-04-04 2025-03-24 Ai Therapeutics Inc Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
CA2416976C (en) * 2000-08-11 2008-05-20 Wyeth Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PL231418B1 (pl) * 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
MXPA03009092A (es) * 2001-04-06 2004-02-12 Wyeth Corp COMBINACIONES DE ANTINEOPLaSICOS COMO RAPAMICINA CON GEMCITABINA O FLUOROURACILO.
CN100496485C (zh) * 2001-06-01 2009-06-10 惠氏公司 抗肿瘤组合
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Similar Documents

Publication Publication Date Title
JP2006519862A5 (cg-RX-API-DMAC7.html)
JP2006524246A5 (cg-RX-API-DMAC7.html)
RU2005130767A (ru) Противоопухолевые композиции, содержащие производное рапамицина и ингибитор ароматазы
Hassin et al. Drugging p53 in cancer: one protein, many targets
ES2985986T3 (es) Conjugado biciclo para tratar el cáncer
RU2005136222A (ru) Противоопухолевые комбинации
Lim et al. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
Ruch et al. Hedgehog signaling pathway and cancer therapeutics: progress to date
JP6994767B2 (ja) Cxcr4阻害剤およびその使用
KR102021157B1 (ko) Akt 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
JP2019521087A5 (cg-RX-API-DMAC7.html)
Marcucci et al. Anti-cancer stem-like cell compounds in clinical development–an overview and critical appraisal
JP2019510832A5 (cg-RX-API-DMAC7.html)
JP2009514870A5 (cg-RX-API-DMAC7.html)
JP2004532883A5 (cg-RX-API-DMAC7.html)
CA2564249A1 (en) Indole and azaindole derivatives with antitumor action
RU2010142390A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
RU2016122654A (ru) Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
RU2020142739A (ru) Ингибиторы mdm2 и их комбинации
JP6002835B2 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JPWO2018117177A1 (ja) Brk阻害化合物
JP2017507151A5 (cg-RX-API-DMAC7.html)
JP2013511526A5 (cg-RX-API-DMAC7.html)
JPWO2021155264A5 (cg-RX-API-DMAC7.html)